Endevica Bio Reports the First Patient Dosing in P-II Study Evaluating TCMCB07 (B07)
Shots:
- Endevica Bio conducting P-II study in collaboration with WuXi Clinical reported the dose administration of B07 in first patient to prevent weight loss in cancer patients diagnosed with stage 4 metastatic colorectal cancer undergoing CT
- In 2024, Endevica Bio completed its P-I study, with early results showing strong safety and efficacy. In current P-II study the 1EP is preventing weight loss and patients will be dosed with B07 while starting CT and during the first several rounds of CT
- B07 is a melanocortin-3/4 receptor antagonist peptide that can cross blood-brain barrier and modulate behavioral & metabolic responses to chronic illness
Ref: Prnewswire | Image: Endevica Bio
Related News:- Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
